The Broadway phase three trial will enroll 2400 patients with established ASCVD on maximally tolerated lipid-lowering therapy, comparing placebo to a new drug over one year.

“Broadway is 2400 patients one year it's looking at drug ascvd patients ASO these are high risk so this is secondary prevention yeah in people who are on their existing maximally tolerated lipid lowering therapy and you're going to Placebo versus drug it's not open label correct yep no no it's placebo-controlled two to one randomization”